Santen Canada Inc., a subsidiary of Santen Pharmaceutical Co., Ltd. (hereinafter, Santen), a global company focused exclusively on ophthalmology, today announced that Verkazia™ (cyclosporine topical ophthalmic emulsion 0.1% w/v) eye drops for the treatment of severe vernal keratoconjunctivitis (VKC) is now listed on the Quebec provincial formulary.
Verkazia™ was approved for the treatment of severe vernal keratoconjunctivitis in children from 4 years of age through adolescence by Health Canada in 2018.1 Santen is pleased to see Verkazia reimbursed for patients living with severe VKC in Quebec, said Carol Stiff, Head of Santen Canada. As a company dedicated to Ophthalmology, we aim to reduce the loss of social and economic opportunities for people around the world due to eye conditions and we hope this decision will help provide more access to this underserved population of Canadians.